Healthcare - Biotechnology - NASDAQ - US
$ 1.8
-7.22 %
$ 53.4 M
Market Cap
-0.95
P/E
CASH FLOW STATEMENT
-49 M
OPERATING CASH FLOW
7.3 M
INVESTING CASH FLOW
28.4 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Immuneering Corporation
| Net Income | -53.5 M |
| Depreciation & Amortization | 352 K |
| Capital Expenditures | -343 K |
| Stock-Based Compensation | 5.73 M |
| Change in Working Capital | -975 K |
| Others | -482 K |
| Free Cash Flow | -49.3 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (53.5) | (50.5) | (33.5) | (17.0) | (7.7) |
| Depreciation & Amortization | 0.4 | 0.8 | 0.2 | 79.3 K | 18.1 K |
| Deferred Income Tax | 0 | 0 | (0.3) | (0.3) | 0.7 |
| Stock Based Compensation | 5.7 | 4.1 | 1.8 | 1.1 | 0.6 |
| Other Operating Activities | (0.6) | (0.2) | 0.1 | 0.3 | 1.5 |
| Change in Working Capital | (1.0) | 1.7 | 0.9 | 1.3 | 0.4 |
| Cash From Operations | (49.0) | (44.1) | (30.9) | (14.6) | (4.4) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (0.3) | (0.7) | 60.8 K | 53.4 K | 20.5 K |
| Other Items | 7.6 | 42.6 | (75.6) | 0 | 0 |
| Cash From Investing Activities | 7.3 | 41.8 | (75.6) | 53.4 K | 20.5 K |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 3.8 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.2 | 19 K | 23.9 | 38.0 | 9.5 |
| Cash From Financing Activities | 28.4 | 19 K | 144.3 | 38.0 | 17.2 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (13.2) | (2.3) | 37.8 | 23.3 | 12.7 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (49.3) | (44.8) | (30.9) | (14.7) | (4.5) |